Sunovion Pharmaceuticals Inc.

Sunovion Pharmaceuticals has been approved by the U.S. Food and Drug Administration for a new drug application to quickly treat Parkinson's disease motor fluctuation episodes, the Marlborough company said Friday.

Sunovion Pharmaceuticals of Marlborough is seeking for the second time U.S. Food and Drug Administration approval for a new drug aimed at helping Parkinson's disease patients.

The Massachusetts biopharma industry has grown by one-third in the past decade, adding nearly 20,000 jobs and putting the state near the top nationally in a fast growing industry.

Marlborough drugmaker Sunovion Pharmaceuticals has named its executive vice president and medical chief as its new CEO beginning next month.

Marlborough drugmaker Sunovion Pharmaceuticals, citing results of a study, said an investigatory drug to treat binge eating disorder has yielded positive results.

Tamura and the Marlborough-based drugmaker are big players in the state's growing life sciences industry, especially in Central Massachusetts.

Sunovion Pharmaceuticals is divesting its allergy and asthma products to focus more heavily on its products that treat chronic obstructive pulmonary disease.

Sunovion Pharmaceuticals Inc. said last week its novel drug candidate dasotraline was successful in treating children with ADHD, showing statistically significant improvements.

Sunovion Pharmaceuticals announced Monday an inhalation powder for the long-term maintenance treatment of airflow obstruction for people with the lung condition known as COPD is now available in the U.S.

Sunovion announced Wednesday it has entered into an exclusive U.S. license agreement with Swiss drugmaker Novartis for three of its lung disease medicines.